By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

SEED Therapeutics announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease and Orphan Drug designations to ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (March Bio), an emerging clinical stage biotechnology company committed to combating ...

Mumbai: Global pharma major Lupin Limited and Avas Pharmaceuticals SRL have announced the launch of Lupin's orphan drug ...

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome ...

Lupin and Avas launch NaMuscla in Italy to treat myotonia in adults with NDM disorders: Our Bureau, Mumbai Tuesday, January 28, 2025, 16:45 Hrs [IST] Global pharma major Lupin Lim ...

Lupin and Avas Launch NaMuscla® in Italy Enables expanded access to the only EU-approved treatment for the myotonia symptoms in adults with non-dystrophic myotonic disorders Mumbai, Zug, January ...

Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) today announced the launch of Lupin’s orphan drug NaMuscla® (mexiletine) in Italy. Avas will commercialize NaMuscla® for ...

Larimar Therapeutics (LRMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Edward ...